The platform is a collaborative video solution that enables doctors and medical staff to deliver seamless health care experiences to patients through this digital interface
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
This test is inexpensive and results are available immediately as compared to the genetic test
The initiative will engage adolescents and youth of India in decisions about their reproductive health
Carestream equipment is highly recommended for its imaging quality
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Subscribe To Our Newsletter & Stay Updated
